2026 Price Guide,FunPep's antibody-inducing peptides

FunPep is at the forefront of pharmaceutical innovation, dedicated to harnessing the power of peptides to develop groundbreaking therapeutic solutions. As a public, late clinical-stage therapeutics company, FunPep has established itself as a leader in functional peptide and antibody-inducing peptide platform technology. Founded in October 2013, this Osaka-based venture company is driven by a mission to contribute to people's well-being by pursuing advanced peptide technology.

The core of FunPep's innovation lies in its deep understanding of peptides, which are compounds formed by 2 to 50 amino acids linked together. When a larger number of amino acids are linked, they are referred to as polypeptides, and the human body is largely composed of polypeptides. FunPep leverages the diverse functions of these peptides to create novel pharmaceutical products, specifically peptide-based medicines.

FunPep's commitment to advancing medical science is evident in its robust research and development pipeline. The company is actively strengthening its R&D efforts through the creation of candidate antibody-inducing peptide compounds against various targets. This strategic focus allows FunPep to explore new avenues for treating a wide range of diseases.

A significant development in FunPep's journey is its FPP004X, an allergy vaccine that is currently undergoing preclinical trials. This innovative therapeutic aims to achieve its effects by stimulating specific biological pathways, marking a crucial step towards novel allergy treatments. The announcement of an option agreement for FunPep's FPP004X underscores the company's progress and the potential of its drug candidates.

Collaborations are also a key aspect of FunPep's strategy for accelerating innovation. A notable partnership with POP BIO Biotechnologies involves combining FunPep's antibody-inducing peptides with POP BIO's SNAP™ platform. This collaboration aims to enhance the production of high levels of these peptides, further solidifying FunPep's position in the biotechnology research landscape. Additionally, FunPep is leveraging artificial intelligence for drug discovery, with Xeureka beginning AI drug discovery support for FunPep's antibody-inducing peptides under a research consignment agreement. This integration of AI signifies FunPep's forward-thinking approach to accelerating the drug development process.

FunPep Co., Ltd. is not just a company; it's a vision for a healthier future. Its dedication to peptide technology extends beyond pharmaceuticals to encompass cosmetics and other fields, showcasing the versatility and potential of its core expertise. The company's operational base in Osaka, Japan, and its significant capital—3.398 billion yen as of December 31, 2024—reflect its strong foundation and ambitious growth plans.

As an innovative medicine venture company, FunPep is poised to make significant contributions to global health. Its focus on developing unique, functional peptides and its strategic collaborations position it as a key player in the future of medicine. The company information and corporate philosophy of FunPep consistently point towards a commitment to scientific excellence and improving human lives through advanced peptide solutions.